The global interest in medical weight loss solutions has surged, driven by the success stories and clinical efficacy of medications like Ozempic and Wegovy. Originally developed for managing Type 2 ...

Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...

Regeneron's trevogrumab trial has proved, overall, successful - potentially providing a solution to a reported Wegovy side ...

A study of real-world and virtual patients suggests that a less frequent dosing of glucagon-like peptide 1 receptor agonists ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

As the Food and Drug Administration clamps down on off-brand weight loss medications, Seattle-area residents are stocking up ...

Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

We are just starting to learn more about the systemic impact of these medications,” Dr. Shiara Ortiz-Pujols told The Post.

The high monthly costs of GLP-1s — ranging from $1,000 to $1,500 — are placing considerable financial pressure on healthcare ...

The researchers found that after 64 weeks, participants had a mean weight loss of −16.7%, with a mean semaglutide dose of 1.08mg/week.

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...